RHOEN-KLINIKUM AG (RHK.DE) Stock Fundamental Analysis
FRA:RHK - Deutsche Boerse Ag - DE0007042301 - Common Stock - Currency: EUR
Overall RHK gets a fundamental rating of 6 out of 10. We evaluated RHK against 25 industry peers in the Health Care Providers & Services industry. RHK is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RHK has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
RHK had positive earnings in the past year.
In the past year RHK had a positive cash flow from operations.
RHK had positive earnings in each of the past 5 years.
Each year in the past 5 years RHK had a positive operating cash flow.
1.2 Ratios
RHK's Return On Assets of 2.56% is in line compared to the rest of the industry. RHK outperforms 58.33% of its industry peers.
RHK has a Return On Equity of 3.66%. This is comparable to the rest of the industry: RHK outperforms 41.67% of its industry peers.
With a Return On Invested Capital value of 2.62%, RHK is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
The Average Return On Invested Capital over the past 3 years for RHK is below the industry average of 5.68%.
The 3 year average ROIC (2.03%) for RHK is below the current ROIC(2.62%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.56% | ||
| ROE | 3.66% | ||
| ROIC | 2.62% |
ROA(3y)1.79%
ROA(5y)1.62%
ROE(3y)2.5%
ROE(5y)2.27%
ROIC(3y)2.03%
ROIC(5y)2.14%
1.3 Margins
The Profit Margin of RHK (3.08%) is comparable to the rest of the industry.
In the last couple of years the Profit Margin of RHK has declined.
The Operating Margin of RHK (3.07%) is comparable to the rest of the industry.
RHK's Operating Margin has declined in the last couple of years.
The Gross Margin of RHK (65.75%) is better than 66.67% of its industry peers.
RHK's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.07% | ||
| PM (TTM) | 3.08% | ||
| GM | 65.75% |
OM growth 3Y25.19%
OM growth 5Y-11.94%
PM growth 3Y191.57%
PM growth 5Y-7.82%
GM growth 3Y-1.13%
GM growth 5Y-0.92%
2. Health
2.1 Basic Checks
RHK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
RHK has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for RHK remains at a similar level compared to 5 years ago.
The debt/assets ratio for RHK has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.17 indicates that RHK is not in any danger for bankruptcy at the moment.
RHK's Altman-Z score of 3.17 is amongst the best of the industry. RHK outperforms 95.83% of its industry peers.
The Debt to FCF ratio of RHK is 2.18, which is a good value as it means it would take RHK, 2.18 years of fcf income to pay off all of its debts.
RHK has a better Debt to FCF ratio (2.18) than 87.50% of its industry peers.
RHK has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of RHK (0.11) is better than 91.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 2.18 | ||
| Altman-Z | 3.17 |
ROIC/WACC0.43
WACC6.15%
2.3 Liquidity
A Current Ratio of 2.34 indicates that RHK has no problem at all paying its short term obligations.
RHK has a Current ratio of 2.34. This is amongst the best in the industry. RHK outperforms 95.83% of its industry peers.
A Quick Ratio of 2.25 indicates that RHK has no problem at all paying its short term obligations.
The Quick ratio of RHK (2.25) is better than 95.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.34 | ||
| Quick Ratio | 2.25 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.17% over the past year.
RHK shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -4.60% yearly.
The Revenue has been growing slightly by 5.33% in the past year.
Measured over the past years, RHK shows a small growth in Revenue. The Revenue has been growing by 3.50% on average per year.
EPS 1Y (TTM)36.17%
EPS 3Y198.79%
EPS 5Y-4.6%
EPS Q2Q%-16.67%
Revenue 1Y (TTM)5.33%
Revenue growth 3Y2.48%
Revenue growth 5Y3.5%
Sales Q2Q%9.63%
3.2 Future
RHK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.50% yearly.
The Revenue is expected to grow by 5.54% on average over the next years.
EPS Next Y40.91%
EPS Next 2Y21.54%
EPS Next 3Y18.92%
EPS Next 5Y17.5%
Revenue Next Year3.64%
Revenue Next 2Y4.24%
Revenue Next 3Y4.53%
Revenue Next 5Y5.54%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 21.94, the valuation of RHK can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of RHK is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 28.47, RHK is valued a bit cheaper.
A Price/Forward Earnings ratio of 22.39 indicates a rather expensive valuation of RHK.
RHK's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 92.74. RHK is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.94 | ||
| Fwd PE | 22.39 |
4.2 Price Multiples
95.83% of the companies in the same industry are more expensive than RHK, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, RHK is valued a bit more expensive than 62.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.22 | ||
| EV/EBITDA | 2.64 |
4.3 Compensation for Growth
RHK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as RHK's earnings are expected to grow with 18.92% in the coming years.
PEG (NY)0.54
PEG (5Y)N/A
EPS Next 2Y21.54%
EPS Next 3Y18.92%
5. Dividend
5.1 Amount
RHK has a Yearly Dividend Yield of 1.38%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.89, RHK pays a bit more dividend than its industry peers.
Compared to the average S&P500 Dividend Yield of 2.28, RHK is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
5.2 History
The dividend of RHK decreases each year by -15.64%.
Dividend Growth(5Y)-15.64%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DP0%
EPS Next 2Y21.54%
EPS Next 3Y18.92%
RHOEN-KLINIKUM AG
FRA:RHK (2/4/2025, 7:00:00 PM)
14.7
+0.1 (+0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.69%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap984.31M
Analysts47.5
Price Target13.77 (-6.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
Yearly Dividend0.15
Dividend Growth(5Y)-15.64%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.9%
EPS NY rev (3m)13.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.16%
Revenue NY rev (3m)1.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.94 | ||
| Fwd PE | 22.39 | ||
| P/S | 0.65 | ||
| P/FCF | 14.22 | ||
| P/OCF | 6.92 | ||
| P/B | 0.77 | ||
| P/tB | 0.9 | ||
| EV/EBITDA | 2.64 |
EPS(TTM)0.67
EY4.56%
EPS(NY)0.66
Fwd EY4.47%
FCF(TTM)1.03
FCFY7.03%
OCF(TTM)2.13
OCFY14.46%
SpS22.57
BVpS19
TBVpS16.39
PEG (NY)0.54
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.56% | ||
| ROE | 3.66% | ||
| ROCE | 3.19% | ||
| ROIC | 2.62% | ||
| ROICexc | 4.2% | ||
| ROICexgc | 5.2% | ||
| OM | 3.07% | ||
| PM (TTM) | 3.08% | ||
| GM | 65.75% | ||
| FCFM | 4.58% |
ROA(3y)1.79%
ROA(5y)1.62%
ROE(3y)2.5%
ROE(5y)2.27%
ROIC(3y)2.03%
ROIC(5y)2.14%
ROICexc(3y)2.6%
ROICexc(5y)2.68%
ROICexgc(3y)3.11%
ROICexgc(5y)3.2%
ROCE(3y)2.47%
ROCE(5y)2.6%
ROICexcg growth 3Y27.2%
ROICexcg growth 5Y-10.8%
ROICexc growth 3Y27.6%
ROICexc growth 5Y-10.47%
OM growth 3Y25.19%
OM growth 5Y-11.94%
PM growth 3Y191.57%
PM growth 5Y-7.82%
GM growth 3Y-1.13%
GM growth 5Y-0.92%
F-Score6
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 2.18 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 115.67% | ||
| Cap/Sales | 4.84% | ||
| Interest Coverage | 14.48 | ||
| Cash Conversion | 129.89% | ||
| Profit Quality | 148.71% | ||
| Current Ratio | 2.34 | ||
| Quick Ratio | 2.25 | ||
| Altman-Z | 3.17 |
F-Score6
WACC6.15%
ROIC/WACC0.43
Cap/Depr(3y)96.73%
Cap/Depr(5y)119.46%
Cap/Sales(3y)4.62%
Cap/Sales(5y)5.96%
Profit Quality(3y)65.77%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.17%
EPS 3Y198.79%
EPS 5Y-4.6%
EPS Q2Q%-16.67%
EPS Next Y40.91%
EPS Next 2Y21.54%
EPS Next 3Y18.92%
EPS Next 5Y17.5%
Revenue 1Y (TTM)5.33%
Revenue growth 3Y2.48%
Revenue growth 5Y3.5%
Sales Q2Q%9.63%
Revenue Next Year3.64%
Revenue Next 2Y4.24%
Revenue Next 3Y4.53%
Revenue Next 5Y5.54%
EBIT growth 1Y49.16%
EBIT growth 3Y28.3%
EBIT growth 5Y-8.87%
EBIT Next Year232.54%
EBIT Next 3Y53.53%
EBIT Next 5Y36.1%
FCF growth 1Y482.32%
FCF growth 3Y41.52%
FCF growth 5YN/A
OCF growth 1Y194.01%
OCF growth 3Y-1.28%
OCF growth 5Y17.1%